<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02517151</url>
  </required_header>
  <id_info>
    <org_study_id>868</org_study_id>
    <nct_id>NCT02517151</nct_id>
  </id_info>
  <brief_title>Iron Supplementation in Inflammatory Bowel Disease (IBD) Patients With Chronic Fatigue</brief_title>
  <acronym>MICI_2011-01</acronym>
  <official_title>Effects of Iron Therapy in Patients With Chronic Fatigue and IBD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 2, randomized, placebo controlled trial evaluating the effects of n intravenous iron
      supplementation on chronic fatigue in IBD patients with controlled disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will evaluate a 6 months therapy with intravenous ferric carboxymaltose.

      Patients will undergo a 2-5 days screening period and then will be treated every 4 weeks with
      iron supplementation/placebo.

      At every visit, hematology and blood iron levels will be evaluated. Treatment will be
      temporarily stopped in case of either Hemoglobin levels above 16 g/dl or ferritin above 800
      ng/ml (level decreased to 500 ng/ml in case of Transferrin-Iron Saturation Percentage above
      50%).

      Study team will be composed of blinded and unblinded personnel and dedicated infusion devices
      will be used to ensure the double blinding.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>chronic fatigue remission</measure>
    <time_frame>Week 24</time_frame>
    <description>Multidimensional fatigue inventory (MFI-20) &lt;13</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chronic fatigue reduction</measure>
    <time_frame>Week 24</time_frame>
    <description>MFI-20 reduction of at least 4 points (absolute MFI-20&gt;13)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chronic fatigue remission</measure>
    <time_frame>Week 12</time_frame>
    <description>MFI-20 &lt;13</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety evaluation</measure>
    <time_frame>week 4, week 12, week 24</time_frame>
    <description>State-Trait Anxiety Inventory (STAI)Y1 and STAI Y2 values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression evaluation</measure>
    <time_frame>week 4, week 12, week 24</time_frame>
    <description>BECK DEPRESSION INVENTORY (BDI-II) values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>week 4, week 12, week 24</time_frame>
    <description>Inflammatory Bowel Disease Questionnaire (IBDQ) values</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Chronic Fatigue</condition>
  <condition>Inflammatory Bowel Disease</condition>
  <arm_group>
    <arm_group_label>Ferric carboxymaltose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg in normal saline (NS) 100 ml administered i.v. at day 0 and then every 4 weeks up to week 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>normal saline (NS) 100 ml administered i.v. at day 0 and then every 4 weeks up to week 24.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferric carboxymaltose</intervention_name>
    <arm_group_label>Ferric carboxymaltose</arm_group_label>
    <other_name>Ferinject</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Ulcerative Colitis or Crohn's Disease established at least 6 months prior
             to Day 1 by endoscopy and/or imaging

          -  At least 6 months of clinical remission (Harvey Bradshaw Index ≤5; Mayo clinical score
             ≤ 2)

          -  Therapy with mesalamine, immunosuppressors or anti-tumor necrosis factor alpha (TNFα)
             at stable doses for at least 3 months prior enrollment; steroids are not permitted
             from 6 months prior baseline

          -  Chronic fatigue symptoms (MFI-20&gt;13)

          -  Iron deficiency: ferritin &lt; 100 microg/l or &lt; 300 microg/l in case of Transferrin-Iron
             Saturation Percentage (TSAT) &lt;20%

          -  Women of childbearing potential must have a negative serum pregnancy test before
             enrollment.

          -  Able and willing to provide written informed consent

        Exclusion Criteria:

          -  Known hypersensibility to active principle or excipients

          -  Pregnant or lactating women

          -  Clinically active IBD (Harvey Bradshaw Index &gt;6; Mayo clinical score &gt;3 or C-Reactive
             Protein &gt;2.5 mg/L

          -  Renal failure (eGFR&lt;60)

          -  History of adrenal insufficiency

          -  History of autoimmune diseases

          -  History of malignancies

          -  Depression

          -  Any current or recent signs or symptoms of viral infectious diseases

          -  Recent psycho-traumatic events

          -  Hemoglobin levels &lt; 12.5 g/dl (men) or &lt;11.5 g/dL (women)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Silvio Danese, MD, PhD</last_name>
    <phone>+39 02 8224</phone>
    <phone_ext>5555</phone_ext>
    <email>IBDclinicaltrials@humanitas.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>IBD Center</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvio Danese, MD, PhD</last_name>
      <phone>0039028224</phone>
      <phone_ext>5555</phone_ext>
      <email>sdanese@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2015</study_first_submitted>
  <study_first_submitted_qc>August 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2015</study_first_posted>
  <last_update_submitted>September 9, 2015</last_update_submitted>
  <last_update_submitted_qc>September 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>iron</keyword>
  <keyword>fatigue</keyword>
  <keyword>crohn's disease</keyword>
  <keyword>ulcerative colitis</keyword>
  <keyword>IBD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

